Skip to main navigation Skip to search Skip to main content

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

  • Efstathios Kastritis
  • , Evangelos Terpos
  • , Maria Roussou
  • , Maria Gavriatopoulou
  • , Constantinos Pamboukas
  • , Ioannis Boletis
  • , Smaragda Marinaki
  • , Theofanis Apostolou
  • , Nikitas Nikitas
  • , Georgios Gkortzolidis
  • , Eurydiki Michalis
  • , Sossana Delimpasi
  • , Meletios A. Dimopoulos*
    • *Corresponding author for this work
  • National and Kapodistrian University of Athens

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science